Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.

摘要 抗体（Abs）通常用于生物医学研究中以鉴定和定量靶点。 proteins.然而，这些Ab的特异性、灵敏度和可靠性可能是可变的，这是一个不确定因素。 这是科学界的重大关注。使用不正确的Ab可能会导致误导 或不准确的结果，阻碍了生物医学研究各个领域的进展。在第一阶段， 项目，我们开发了工具来验证用于检测的商业抗体的特异性 我们开发并发表了一种方法， 奶昔我们将介绍第一阶段工作的一些结果，这些结果表明， 迫切需要解决这一问题。这一拟议的SBIR第二阶段项目旨在扩大和 将第一阶段的工作商业化。我们将继续开展第一阶段启动的抗体验证工作， 将分析扩展到其他类型的蛋白质翻译后修饰（PTM）， Western分析和流式细胞术。第二阶段项目还寻求改善和扩大这一点， 管道进一步，并开发新的方法来验证抗体对糖基化蛋白， 通常是动态的，使用传统技术检测具有挑战性。我们还将聘请 测量抗体混杂的创新工具，使用我们称之为“Sundae”的技术， 研究Ab互补位的特异性。Sundae将展示两种治疗性抗体。 第二阶段项目有几个关键目标，包括开发新的抗体特异性 分析和建立用于共享经验证的抗体数据的集中数据库。项目 该团队由抗体验证、蛋白质组学和分子生物学方面的专家组成， 与我们当前和未来的行业合作伙伴和学术研究人员密切合作，以确保我们的 成功

ABSTRACT Antibodies (Abs) are commonly employed in biomedical research to identify and quantify target proteins. However, the specificity, sensitivity and reliability of these Abs can be variable, which is a significant concern in the scientific community. The use of an incorrect Ab can result in misleading or inaccurate results, impeding progress in various areas of biomedical research. In Phase I of this project, we developed tools to validate the specificity of commercial Abs used to detect phosphorylated sites in proteins in a method we developed and published that we named MILKSHAKE. We will present some of these results from this Phase I effort, which demonstrates the critical need to address this concern. This proposed SBIR Phase II project aims to both extend and commercialize the Phase I effort. We will continue the Ab validation work initiated in Phase I by extending the analysis to other types of post-translational modifications (PTMs) of proteins in Western analysis and flow cytometry. This Phase II project also seeks to improve and scale this pipeline further, and to develop new methods for validating Abs against glycosylated proteins, which are often dynamic and challenging to detect using traditional techniques. We will also employ an innovative tool for measuring Ab promiscuity using a technology we term ‘Sundae’ to better investigate the specificity of the Ab paratope. Sundae will be demonstrated for two therapeutic Abs. The Phase II project has several key objectives, including the development of new Ab-specific assays and the establishment of a centralized database for sharing validated Ab data. The project team comprises experts in Ab validation, proteomics, and molecular biology, and will collaborate closely with our current and future industry partners and academic researchers to ensure our success.